Table 1.
Prospective randomized trials of stem cell therapy in acute myocardial infarction.
| Study | No. of Patients | LVEF (%) Baseline | Follow-up (Months) | Cell Type | Delivery Route | LVEF Increase (%) |
| ASTAMI (2006) | 100 | 46 | 6 | BMC | IC | No effect |
| FINCELL (2008) | 80 | 58.8 | 6 | BMC | IC | 7.1 |
| REGENT (2009) | 200 | 36 | 6 | BM-MNC / CD 34+ / CXCR4+ |
IC | No effect |
| BOOST (2009) | 60 | 51 | 6 | BMC | IC | 6.7 |
| BONAMI (2010) | 101 | 36.3 | 3 | BMC | IC | No Effect |
| REPAIR-AMI (2010) | 204 | 45.4 | 24 | BMC | IC | 4.7 |
| HEBE (2011) | 200 | 38.6 | 4 | BMC | IC | No Effect |
| TOPCARE (2011) | 59 | 46 | 60 | CPC / BMC | IC | 11 |
| Late Time (2011) | 87 | 48.7 | 6 | BM-MNC | IC | No Effect |
LVEF: left ventricular ejection fraction; BMC: bone marrow-derived cells; BM-MNC: bone marrow-derived unselected mononuclear cells; CPC: circulating progenitor cells; IC: intracoronary.